Mobile website
Clinical Research
Expressions of Ki-67 and LRP in different subtypes of breast cancer and their clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Abstract Objective:To investigate the expressions of Ki-67 and LRP in different breast cancer subtypes and the relevant clinical significance. Methods: Breast cancer specimens were collected from 203 patients who underwent operation in the Affiliated Tumor Hospital of Xinjiang Medical University during Jan. to Oct. 2009. The expression of ER, PR, HER2, Ki-67 and LRP in the breast cancer tissues was determined by immunohistochemical staining. Ki-67 and LRP expression and its correlation with clinical and pathological features of different breast cancer subtypes was analyzed. Results: Four breast cancer subtypes were identified with different ER, PR and HER2 gene expression patterns. There were significant differences in tumor sizes, clinical stages, histological grades, lymph node metastases, and patient’ ages between the 4 breast cancer subtypes(P<0.05), but not in cancer type. Ki-67 and LRP proteins were highly expressed in Luminal B(ER/PR+, HER2+) breast cancer(93.2%, 86.2%, P<0.05), but the expression of the two was not correlated with each other(r=0.144, P>0.05). The chemotherapy efficiency for LRP-positive Luminal B patients was lower than that in LRP-negative Luminal B patients(39.4% vs 83.3%, P<0.05), while the chemotherapy efficiencies between Ki-67-positive and negative Luminal B patients were not significantly different(P>0.05). Conclusion: Expression of Ki-67 and LRP proteins varies in different breast cancer subtypes. Overexpression of LRP in Luminal B breast cancer might be correlated with the chemotherapy efficiency after surgery.
Keywords:
Project Supported:
Clc Number:
